Ready to get scared? Edmonton’s iconic Deadmonton Haunted House has revealed its 2025 themes — and they’ll send chills down ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

In the EMPEROR trial, children with a confirmed variant in the SCN1A gene not associated with gain-of-function mutations will receive zorevunersen or a placebo.

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Takeda Pharmaceutical Company saw its drug Entyvio (vedolizumab) approved in China by the National Medical Products ...

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

The University of Copenhagen is excited to announce Gordian Biotechnology as a Tier 5 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in ...